Previous 10 | Next 10 |
Gainers: Bone Biologics (BBLG) +13%. Akero Therapeutics AKRO +10%. Biotricity (BTCY) +9%. Jasper Therapeutics (JSPR) +7%. Burning Rock Biotech (BNR) +6%. Losers: AC Immune ACIU -17%. Arcellx ACLX -17%. SOPHiA GENETICS (SOPH) -16%. AirSculpt Te...
AC Immune (ACIU) -32% as crenezumab fails in Alzheimer's study. Cango (CANG) -30%. Absci (ABSI) -14%. Hillstream BioPharma (HILS) -11%. Cepton (CPTN) -7%. Enservco Corporation (ENSV) -10%. Arcellx (ACLX) -10% on upsizing of follow-on public offering of 7M shares at $...
Crenezumab did not statistically significantly slow or prevent cognitive decline in people with a specific genetic mutation which causes early-onset Alzheimer’s disease Numerical differences favouring crenezumab over placebo were observed across the co-primary, multiple s...
The following slide deck was published by AC Immune SA in conjunction with this event. For further details see: AC Immune (ACIU) Investor Presentation - Slideshow
LAUSANNE, Switzerland, May 31, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that company management will participate in a fireside chat and one-on-one investor m...
LAUSANNE, Switzerland, May 17, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Dr. Andrea Pfeifer, CEO and a Director of AC Immune, will be awarded the prestig...
First study of an anti-Abeta vaccine in people living with Down syndrome (DS) Immune response and Alzheimer’s disease (AD) biomarkers showed positive impact of ACI-24 first gen...
AC Immune press release (NASDAQ:ACIU): Q1 GAAP EPS of -CHQ0.23 in-line. Q1 Net loss of CHQ18.84M For further details see: AC Immune GAAP EPS of -$0.23 in-line
Two clinical readouts delivered in Q1; five more expected by year-end Interim data from the Phase 1b/2a trial of ACI-35.030 confirm the favorable safety and potent immunogenicity of this first-in-class anti-pTau vaccine First images of alpha-synuclein in patients’...
LAUSANNE, Switzerland, April 27, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company Management will participate in a Fireside chat and one-on-one investor...
News, Short Squeeze, Breakout and More Instantly...
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 Three oral presentations at the Alzheimer’s Association International Conference (AAIC 2024), including talks on morADC, ACI-24.060,...
2024-05-30 18:30:02 ET BTIG analyst issues BUY recommendation for ACIU on May 30, 2024 04:49PM ET. ACIU was trading at $3.97 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendations . ...
2024-05-30 18:00:07 ET Thomas Shrader from BTIG issued a price target of $8.00 for ACIU on 2024-05-30 16:49:00. The adjusted price target was set to $8.00. At the time of the announcement, ACIU was trading at $3.97. The overall price target consensus is at $10.00 with hi...